The Lancet Oncology最新文献

{"title":"CONTACT-02: limited clinical benefit and a suboptimal control group","authors":"Dries Develtere","doi":"10.1016/s1470-2045(25)00418-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00418-8","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AJCC9V classification for HPV-positive oropharyngeal carcinoma – Authors' reply","authors":"Allen S Ho, Shao Hui Huang, William M Lydiatt, Zachary S Zumsteg","doi":"10.1016/s1470-2045(25)00554-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00554-6","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"101 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CONTACT-02: limited clinical benefit and a suboptimal control group – Authors' reply","authors":"Neeraj Agarwal, Axel S Merseburger, Svetlana Andrianova, Arun A Azad","doi":"10.1016/s1470-2045(25)00538-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00538-8","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital health and artificial intelligence innovations for oncology in sub-Saharan Africa","authors":"Farouk Dako, Fabio Y Moraes, Florence Doo, Mohammed Abed, Udunna Anazodo, Labenyimoh Patrick, Fernanda M Favorito, Emadelden Fouad, Adewumi Alabi, Stephen Avery, Andrew Scott, Wilfred Ngwa, Hedvig Hricak","doi":"10.1016/s1470-2045(25)00360-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00360-2","url":null,"abstract":"Countries across Africa are experiencing the dual challenge of rising cancer burden and severe health-care workforce shortages, which threaten to overwhelm its already strained health systems. Simultaneously, advancements in digital health technologies, including electronic health records, telemedicine, mobile health, and artificial intelligence (AI), offer promising solutions to address these challenges. This Policy Review explores the potential of digital health innovations to transform cancer care in Africa by improving access, efficiency, and equity. It highlights successful examples, such as AI-driven diagnostic tools and mobile health interventions, while addressing barriers to adoption, including infrastructure gaps, poor digital literacy, and policy constraints. Strategic recommendations are proposed to foster sustainable and scalable digital health ecosystems tailored to the African context. By leveraging digital health and AI, countries in Africa have a unique opportunity to improve oncology outcomes and strengthen their health-care infrastructure.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healing a fractured world: mRNA therapies to take centre stage?","authors":"","doi":"10.1016/s1470-2045(25)00558-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00558-3","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"69 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BrECADD and fertility: an ongoing concern","authors":"Virginie Barraud-Lange, Mathilde Bourdon, Mathilde Cavalieri, Christine Decanter, Florian Chevillon","doi":"10.1016/s1470-2045(25)00482-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00482-6","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More is not always more for older patients with multiple myeloma","authors":"Kenneth H Shain","doi":"10.1016/s1470-2045(25)00357-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00357-2","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","authors":"Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Borhane Slama, Lionel Karlin, Frédéric Orsini Piocelle, Mamoun Dib, Laurence Sanhes, Pierre Morel, Abderazzak El Yamani, Mourad Tiab, Reza Tabrizi, Valentine Richez, Laurent Garderet, Thierry Facon","doi":"10.1016/s1470-2045(25)00280-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00280-3","url":null,"abstract":"<h3>Background</h3>Patients with frailty and newly diagnosed multiple myeloma have worse outcomes due to higher rates of adverse events (AEs) and treatment discontinuation. This study evaluated a dexamethasone-sparing regimen of daratumumab plus lenalidomide versus lenalidomide plus dexamethasone in frail patients with newly diagnosed multiple myeloma.<h3>Methods</h3>In this prospective, randomised, open-label trial, conducted at 61 active Intergroup Francophone of Myeloma centres, patients aged 65 years or older with newly diagnosed multiple myeloma and an Eastern Cooperative Oncology Group proxy frailty score of 2 or more were randomly assigned 2:1 to receive daratumumab (1800 mg subcutaneously) plus oral lenalidomide (25 mg daily for 21 days of a 28 day cycle) and dexamethasone (20mg weekly) for two cycles (dexamethasone-sparing group) or lenalidomide (25 mg daily) and oral dexamethasone (20 mg weekly; control group), with stratification by International Staging System, age, and centre. The primary endpoint was progression-free survival. Efficacy was assessed in the intention-to-treat population and safety was assessed in all patients exposed to at least one dose of randomised intervention. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT03993912</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and is complete.<h3>Findings</h3>From Oct 18, 2019 to July 20, 2021, 335 patients were screened, of whom 295 patients were randomly assigned (200 to lenalidomide plus daratumumab, 95 to lenalidomide plus dexamethasone). The median age was 81 years (IQR 77–84), with 180 (61%) aged older than 80 years, and 151 (51%) patients were female and 144 (49%) were male. Median follow-up was 46·3 months (IQR 46·0–52·7). Median progression-free survival was 53·4 months (95% CI 35·3–not reached) in the dexamethasone-sparing group versus 22·5 months (16·5–39·0) in the control group (hazard ratio [HR] 0·51, 95% CI 0·37–0·70, p<0·0001). The most common grade 3–5 AEs were neutropenia (110 [55%] of 200 patients in the dexamethasone-sparing group <em>vs</em> 23 [24%] of 95 patients in the control group), and infection (38 [19%] <em>vs</em> 20 [21%]). Serious adverse events occurred in 126 patients (63%) in the dexamethasone-sparing group and 66 patients (69%) in the control group. AEs leading to death occurred in 23 patients (12%) in the dexamethasone-sparing group and 12 patients (13%) in the control group, with 4 (2%) and 2 (2%) grade 5 treatment-emergent adverse events, respectively.<h3>Interpretation</h3>In the IFM2017-03 trial, use of lenalidomide plus daratumumab, wi","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"202 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Oncol 2025; 26: e423–35","authors":"","doi":"10.1016/s1470-2045(25)00560-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00560-1","url":null,"abstract":"<em>Concin N, Matias-Guiu X, Cibula D, et al. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025.</em> Lancet Oncol <em>2025; <strong>26:</strong> e423–35</em>. In this Policy Review, several typographical, formatting, language, and editing errors have been identified. These corrections have been made to the online version as of Sept 29, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"105 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study","authors":"Alessandro Di Federico, Kaiwen Wang, Monica F Chen, Adam A Barsouk, Arianna Pagliaro, Lanyi N Chen, Francesca R Ogliari, Paul Stockhammer, Rajat Thawani, Shahm Raslan, Eleonora Gariazzo, Francesca Fusco, Grace M Hambelton, Fabrizio Citarella, David Meyer, Mihaela Aldea, Andrea De Giglio, Joao V Alessi, Federica Pecci, Francesco Gelsomino, Biagio Ricciuti","doi":"10.1016/s1470-2045(25)00409-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00409-7","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Patients with &lt;em&gt;BRAF&lt;/em&gt;&lt;sup&gt;V600E&lt;/sup&gt; (ie, Val600Glu)-mutated non-small-cell lung cancer (NSCLC) can be treated with BRAF and mitogen-activated protein kinase (MEK) inhibitors, or with immune checkpoint inhibitors (ICIs) with or without chemotherapy. We aimed to investigate which initial systemic treatment should be prioritised in this population.&lt;h3&gt;Methods&lt;/h3&gt;In this retrospective cohort study conducted across 17 centres in the USA, Italy, France, and Brazil, clinicopathological data were collected from participants aged 18 years and older with stage IV, treatment-naive, metastatic &lt;em&gt;BRAF&lt;/em&gt;&lt;sup&gt;V600E&lt;/sup&gt;-mutated NSCLC and with an Eastern Cooperative Oncology Group performance status of 0–3, who started first-line treatment with ICIs with or without chemotherapy (PD-1 or PD-L1 inhibitors with or without platinum-based chemotherapy) or BRAF and MEK inhibitors (dabrafenib and trametinib or encorafenib and binimetinib) between Jan 2, 2015, and July 11, 2024. The primary endpoint was overall survival with first-line ICIs with or without chemotherapy versus with BRAF and MEK inhibitors.&lt;h3&gt;Findings&lt;/h3&gt;284 participants were identified for this study, of whom 88 (31%) received ICIs with or without chemotherapy and 196 (69%) received BRAF and MEK inhibitors. The median age of participants was 68 years (IQR 61–74), and 148 (52%) participants were female and 136 (48%) male. Participants in the ICIs with or without chemotherapy group had a higher history of smoking (73 [83%] &lt;em&gt;vs&lt;/em&gt; 118 [60%]; p=0·0002) and a higher PD-L1 expression (≥50% in 58 [66%] &lt;em&gt;vs&lt;/em&gt; 76 [39%], 1–49% in 16 [18%] &lt;em&gt;vs&lt;/em&gt; 67 [34%], and &lt;1% in eight [9%] &lt;em&gt;vs&lt;/em&gt; 31 [16%]; p=0·0003) than those in the BRAF and MEK inhibitor group. At a median follow-up time of 45·0 months (95% CI 39·0–55·7), ICIs with or without chemotherapy were associated with improved median overall survival compared with BRAF and MEK inhibitors (40·9 months [95% CI 33·3–not reached] &lt;em&gt;vs&lt;/em&gt; 25·2 months [19·9–31·1]; hazard ratio [HR] 0·69 [0·49–0·98], p=0·039). In subgroup analyses, ICIs with or without chemotherapy, compared with BRAF and MEK inhibitors, were associated with longer median overall survival in participants with a history of smoking (HR 0·60 [0·40–0·90], p=0·013), with a PD-L1 tumour proportion score of ≥1% or higher (HR 0·66 [0·45–0·98], p=0·039), aged 70 years or older (HR 0·54 [0·31–0·94], p=0·029), with &lt;em&gt;TP53&lt;/em&gt; co-mutations (HR 0·46 [0·27–0·79], p=0·0048), and without brain metastases (HR 0·66 [0·45–0·99], p=0·045). With BRAF and MEK inhibitors, frequencies of adverse events of any grade and of grade 3 and higher were similar whether administered as first-line therapy or as second-line therapy following ICIs with or without chemotherapy.&lt;h3&gt;Interpretation&lt;/h3&gt;First-line ICIs with or without chemotherapy were associated with improved overall survival compared with BRAF and MEK inhibitors in participants with metastatic &lt;em&gt;BRAF&lt;/em&gt;&lt;sup&gt;V","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}